Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03323164 · ClinicalTrials.gov registry record · Phase 4
Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
A Phase 4 study, sponsored by Wills Eye.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
NCT03323164 is a Phase 4 study that has completed, run by Wills Eye. The registered enrollment target is 35 participants.
The verdict
NCT03323164, a Phase 4 study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study evaluates the possible acute changes in peripapillary blood flow after instillation of antiglaucoma medications in patients with primary open angle glaucoma (POAG), normal tension glaucoma (NTG), or ocular hypertension (OHTN) using Optical Coherence Tomography (OCT) angiography.
Interventions
- DRUG Timolol Maleate
- DRUG Brimonidine Tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-07-10 |
| Est. Completion | 2020-05-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03323164
The ClinicalTrials.gov registry entry for NCT03323164 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Timolol Maleate is the first listed.
NCT03323164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03323164 about?
NCT03323164 is a clinical study titled "Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study". This study evaluates the possible acute changes in peripapillary blood flow after instillation of antiglaucoma medications in patients with primary open angle glaucoma (POAG), normal tension glaucoma (NTG), or ocular hypertension (OHTN) using Optical Coherence Tomography (OCT) angiography.
What is the current status of trial NCT03323164?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2017-07-10. Estimated completion is 2020-05-30.
What interventions are being tested in trial NCT03323164?
The interventions under investigation include: Timolol Maleate (DRUG), Brimonidine Tartrate (DRUG).
Who is sponsoring clinical trial NCT03323164?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.